Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SoftOx Solutions AS ( (DE:6FV) ) has shared an announcement.
SoftOx Solutions AS has announced breakthrough data on the stability of hypochlorous acid (HOCl), a key component of its inhaled therapy for cystic fibrosis. The study shows that storing HOCl as a solid precursor enhances stability, marking a pivotal moment for the company’s inhaled SIS program. The upcoming proof-of-concept trial in early 2026 aims to evaluate safety and efficacy, potentially expanding treatment indications beyond cystic fibrosis.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company specializes in developing pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, leveraging extensive research and development collaborations with leading Nordic research institutes.
Average Trading Volume: 20,626,568
Current Market Cap: NOK188.1M
For an in-depth examination of 6FV stock, go to TipRanks’ Overview page.